Abstract
Is cabazitaxel a therapeutic second-line option for patients with castrate-resistant prostate cancer?
Full Text
Sign-in/Register to access full text options
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have